Harpoon Therapeutics Corp - נכסים נקיים למניה בודדת HARP

The current book value per share reflects the financial standing of Harpoon Therapeutics (HARP), where the value 1.12 determines the parameter status. Capital dynamics are driven by an acquisition by a tech giant for the global implementation of T-cell activators. Drug development is based on strict ethical standards and environmental safety. The expert team is sustained by the ability to create innovations with the support of the largest pharmaceutical behemoths.

To objectively evaluate the issuer, a manager requires a net asset value per share calculation, which determines the residual value of the business after all liabilities are settled. By analyzing the book value per share, an investor sees the real capital of Harpoon Therapeutics (HARP), backed by the protected TriTAC patent platform and the integration of R&D assets into oncology holdings, which creates a fundamental foundation of stability.